DNA at a glance
Ginkgo Bioworks Holdings, Inc. (DNA, SEC CIK 1830214) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $170.2 million (down 25.1% from FY2024) and a net loss of $312.8 million. Diluted EPS was -$5.64.
- The most recent insider open-market sale reported on Form 4 was by Kelly Jason R on October 19, 2026 of 45,682 shares at $10.14 per share.
- In the last 90 days, DNA insiders reported 0 open-market purchases ($0) and 9 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $170.2M
- −25.1% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$1.4M
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $27.7M, down $1.7M YoY from $29.4M, driven by reduced agriculture customer services
- Operating margin (157.5%) vs (280.1%) YoY, based on operating losses of $43.6M and $82.3M
- Cell engineering tools costs $1.8M vs $4.6M, benefiting from lower lab automation equipment expenses
- Cash, equivalents and marketable securities $285.4M, sufficient through at least the next 12 months
- Nine-month operating cash flow $(117.0)M, ATM proceeds $23.0M, expenditures expected to exceed revenue through next 12 months
Risk Factors
- No material changes to 2025 Annual Report risk factors
- Investment risk: potential loss of all or part of invested capital
- Business risk: adverse effects on prospects, financial condition, or operating results
- Carried-forward risk details unavailable in provided section
AI summary of the DNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Ginkgo issued third-quarter fiscal 2026 results for the period ended September 30, 2026
- Results press release furnished as Exhibit 99.1, containing the substantive financial details
Item EX-99.1: Item EX-99.1
- Q3 revenue $27.7M, down 6% year over year but up from $20M in Q2, signaling sequential stabilization
- GAAP loss from continuing operations narrowed to $41.0M from $73.4M, while Adjusted EBITDA loss improved to $22M from $53M
Item EX-99.1: Item EX-99.1
- Q3 2026 results presentation scheduled for November 5, 2026, at 4:30 p.m. ET
- Results cover quarter ended September 30, 2026
Item 7.01: Regulation FD Disclosure
- Q3 2026 business-performance presentation scheduled for November 5, 2026 at 4:30 p.m. ET
- Webcast, investor Q&A, and replay available through Ginkgo’s investor-relations website
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results released for quarter ended June 30, 2026
- Full financial figures and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $20.2M, down 48% from $39.1M, reflecting restructuring-driven program rationalization
- Continuing-operations net loss widened to $57.3M from $53.2M; Adjusted EBITDA loss reached $36.3M versus $25.4M
AI summaries of DNA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DNA
Don't miss the next DNA filing
- Alerts as it files. A push when DNA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DNA, by share count.
- Ask anything. An AI agent that reads every DNA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kelly Jason R | Sell | Oct 19, 2026 | 45,682 | $10.14 |
| Canton Barry | Sell | Oct 19, 2026 | 18,803 | $10.14 |
| Shetty Reshma P. | Sell | Oct 19, 2026 | 22,369 | $10.14 |
| Canton Barry | Sell | Oct 19, 2026 | 22,369 | $10.14 |
| Shetty Reshma P. | Sell | Oct 19, 2026 | 18,803 | $10.14 |
| Coen Steven P. | Sell | Oct 19, 2026 | 766 | $10.14 |
| Coen Steven P. | M | Oct 16, 2026 | 1,174 | - |
| Coen Steven P. | M | Oct 16, 2026 | 312 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $251.5M | $227.0M | $170.2M |
| Operating Income | - | -$559.8M | -$315.3M |
| Net Income | -$892.9M | -$547.0M | -$312.8M |
| Op. Margin | - | -246.5% | -185.3% |
| Net Margin | -355.1% | -240.9% | -183.8% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.1B |
| Equity | - | $716.1M | $508.6M |
| ROE | - | -76.4% | -61.5% |
| Per Share | |||
| EPS | $-0.46 | $-10.54 | $-5.64 |
| Cash Flow | |||
| Operating CF | - | -$319.6M | -$171.1M |
| CapEx | $40.8M | $62.5M | $7.7M |
Source: XBRL data in Ginkgo Bioworks Holdings, Inc. (DNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
DNA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 21, 2026 | - | - | - |
| 4 | Oct 21, 2026 | - | - | - |
| 4 | Oct 21, 2026 | - | - | - |
| 4 | Oct 21, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | May 26, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
DNA SEC filings: frequently asked questions
Are DNA insiders buying or selling?
In the last 90 days, Ginkgo Bioworks Holdings, Inc. (DNA) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $1.4 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was DNA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $170.2 million (down 25.1% from FY2024) and a net loss of $312.8 million. Diluted EPS was -$5.64. The figures come from the XBRL data in the 10-K.
What did DNA report in its latest 8-K?
Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Ginkgo issued third-quarter fiscal 2026 results for the period ended September 30, 2026.
What are the latest DNA SEC filings?
Ginkgo Bioworks Holdings, Inc. (DNA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 21, 2026.
What is DNA's SEC CIK number?
Ginkgo Bioworks Holdings, Inc. (DNA)'s SEC Central Index Key (CIK) is 1830214. EDGAR lists every DNA filing under that number.
Ask anything about DNA
The research agent reads DNA's filings, financials, insider trades and 13F holders, then answers with sources.